Glp1 Vs Contrave Weight Management

Prescription weight loss medications have come a long way. If you're weighing your options, the GLP-1 vs Contrave comparison is one worth understanding. These are two fundamentally different classes of medication (one is an injectable peptide, the other is an oral combination pill. They work through different brain pathways, produce different levels of weight loss, and come with different side effect profiles.

Key Takeaways: - Learn how each medication works - Weight Loss Results Head-to-Head - Side Effects Compared - Cost, Access, and Daily Experience

Here's what the evidence says about each one, so you can have an informed conversation with your provider.

How Each Medication Works

Feature	GLP-1 Medications	Contrave
Mechanism	GLP-1 receptor agonist	Naltrexone + bupropion
Administration	Weekly injection	Oral (twice daily)
Weight loss (trials)	15-22%	~5-8%
Appetite target	Hormonal hunger signals	Brain reward circuits
FDA approved	Yes (multiple)	Yes (2014)
Common side effects	Nausea, GI symptoms	Nausea, headache, insomnia
Cost (brand)	$1,000-$1,500/mo	$300-$400/mo

"The conversation about obesity needs to shift from willpower to biology. These medications work because obesity is a neuroendocrine disease, not a character flaw.") Dr. Fatima Cody Stanford, MD, MPH, Massachusetts General Hospital

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) mimic a natural gut hormone. When you eat, your intestines release GLP-1, which tells your brain you're full, slows stomach emptying, and helps regulate blood sugar. GLP-1 medications amplify this process. The result is genuine appetite reduction (you're not fighting cravings with willpower, your hunger signals are actually quieter.

Contrave is a combination of two existing drugs: naltrexone and bupropion. Naltrexone is an opioid antagonist originally used for addiction treatment. Bupropion is an antidepressant (also marketed for smoking cessation). Together, they act on brain reward circuits and appetite-regulating centers in the hypothalamus.

The theory behind Contrave is that bupropion activates neurons that reduce appetite, while naltrexone blocks the self-inhibiting feedback loop that would normally limit bupropion's appetite-suppressing effect. It targets the "reward" aspect of eating) the pleasure signals that drive overeating (rather than the hormonal hunger signals that GLP-1 medications address.

Think of it this way: GLP-1 medications make you less hungry. Contrave makes food less rewarding. Both reduce food intake, but through different mechanisms.

If you're exploring whether a GLP-1 medication fits your health profile, .

Weight Loss Results Head-to-Head

The clinical data on weight loss is clear, and the gap is significant.

GLP-1 medications produce more weight loss. Semaglutide 2.4 mg weekly showed average weight loss of about 15% of body weight in the STEP trials. Tirzepatide at its highest dose produced up to 22.5% in SURMOUNT trials. These are significant numbers for many patients.

---

Free Download: Decision Matrix GLP-1 vs Contrave) compare weight loss data, side effects, cost, and daily experience side by side. Get yours free (we'll email it to you instantly. [Download Now]

---

Contrave produces more modest results. In the COR (Contrave Obesity Research) clinical trials, average weight loss was about 5-8% of body weight over 56 weeks. For a 220-pound person, that's roughly 11-18 pounds. Meaningful, but substantially less than what GLP-1 medications deliver.

A key nuance: not everyone needs or wants maximum weight loss. For someone who needs to lose 15-20 pounds and is uncomfortable with injections, Contrave may be an appropriate option. For someone who needs to lose 50+ pounds or has obesity-related health conditions, GLP-1 medications typically offer a better risk-benefit profile.

Response rates also differ. About 50% of Contrave users achieve at least 5% weight loss. With semaglutide, over 85% of participants achieved 5% weight loss, and about a third lost 20% or more. The likelihood of a meaningful response is higher with GLP-1 therapy.

For detailed semaglutide information, read our .

Side Effects Compared

The side effect profiles are quite different because the drugs work through different systems.

GLP-1 side effects are primarily gastrointestinal: nausea, vomiting, diarrhea, constipation, and decreased appetite. These typically improve during the first 4-8 weeks of treatment as your body adjusts. Dose titration) starting low and increasing gradually (helps minimize these symptoms.

Contrave side effects reflect its neurological mechanisms. The most common are nausea (shared with GLP-1s), constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. The bupropion component carries a boxed warning about increased risk of suicidal thoughts and behaviors, particularly in young adults. This is the most significant safety concern.

Contrave is contraindicated in people with seizure disorders, eating disorders (bulimia or anorexia), uncontrolled hypertension, or chronic opioid use. It also cannot be used with MAO inhibitors. These contraindications are important screening criteria.

GLP-1 medications carry warnings about pancreatitis, gallbladder disease, and (from animal studies) thyroid tumors. They should be used cautiously in people with a history of medullary thyroid cancer or MEN 2 syndrome.

One practical difference: if you experience severe side effects, Contrave clears your system within a few days. Weekly GLP-1 medications have longer half-lives, meaning side effects take longer to resolve after stopping.

Our covers strategies for handling GI symptoms on GLP-1 therapy.

Cost, Access, and Daily Experience

Cost comparison favors Contrave in some cases. Generic naltrexone/bupropion is available and costs significantly less than brand-name Contrave. Brand-name Contrave runs around $300-400 per month without insurance.

Brand-name GLP-1 medications exceed $1,000 per month without insurance. However, compounded semaglutide through licensed 503A pharmacies can bring costs down substantially. for current rates.

Daily experience differs too. Contrave is an oral tablet taken twice daily (one tablet in the morning, one in the evening. No injections, no refrigeration. The titration period takes about 4 weeks to reach the full dose of two tablets twice daily.

GLP-1 medications like semaglutide require one subcutaneous injection per week. The injection takes 30 seconds. Some people strongly prefer the simplicity of swallowing a pill. Others prefer getting everything done in one weekly injection.

Insurance coverage varies. Many plans cover Contrave for weight management. GLP-1 coverage is less consistent, especially for weight loss indications versus diabetes. Compounded options through FormBlends provide a predictable out-of-pocket cost regardless of insurance status.

Track your progress on any weight management medication with the .

Frequently Asked Questions

Can I take Contrave and a GLP-1 medication together?

This combination is not standard practice. Both medications reduce appetite through different mechanisms, and combining them could increase side effects without proportionally better results. Some providers have used them together in specific cases, but this should only be done under close medical supervision.

Which medication is better for emotional eating?

Contrave may have an edge for emotional or reward-driven eating because it targets brain reward circuits directly. GLP-1 medications reduce physical hunger but may be less effective at addressing the psychological component of eating. For many people, the appetite reduction from GLP-1 therapy is sufficient to reduce all types of overeating.

Does Contrave work for people with diabetes?

Contrave is not specifically approved for diabetes management and does not lower blood sugar the way GLP-1 medications do. If you have type 2 diabetes and need weight loss, GLP-1 medications offer dual benefits) weight reduction and blood sugar improvement (making them the preferred choice for most providers.

How long do I need to take either medication?

Both are typically used long-term. Stopping either medication often leads to weight regain. Your provider will develop a plan that may include ongoing medication, dose adjustments over time, and lifestyle strategies to maintain results. Building sustainable habits during treatment improves long-term outcomes.

Let's Make This Happen

The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide) no pressure, no commitment.

---

Sources & References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
8. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
11. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
12. Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827

This content is provided for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare provider with any questions about a medical condition or treatment plan.

Last updated: 2026-03-24